3 ms·
>if they get patients with even worse reaction or even dying from it, it could kill the therapy for good in Phase I. Perhaps. Or perhaps not. It depends. If it
by aestra 12y ago
>if they get patients with even worse reaction or even dying from it, it could kill the therapy for good in Phase I.
Perhaps. Or perhaps not. It depends. If it shows to be safer than a bone marrow transplant (insanely dangerous) its got potential.
It's all a benefits/risk analysis.
- zenbuzzfizz 12y agoYou are thinking of allogeneic bone marrow transplants (bone marrow is transplanted from a donor) where there is a 20% chance of death. Typically, myeloma patients get autologous transplants (the patient self donates bone marrow stem cells) which are much less dangerous (less than 5% death rate). I know someone who has had five ASCTs (autologous stem cell transplants) and he is still kicking. It's not a cake walk but at least you don't die.